Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22060199 | 0.78 | MEN1 (0.46) | MEN1KMT2AEPHX1POLB | |
| SCHEMBL19035755 | 0.72 | POLB (0.37) | MEN1KMT2AEPHX1POLBHTT | |
| SCHEMBL10211106 | 0.69 | — | — | |
| SCHEMBL1276388 | 0.67 | MEN1 (1.00) | MEN1KMT2AEPHX1POLBHTT | |
| SCHEMBL2833590 | 0.67 | MEN1 (0.60) | MEN1KMT2AEPHX1POLBHTT | |
| SCHEMBL19484935 | 0.65 | MEN1 (0.43) | MEN1KMT2AEPHX1POLBHTT | |
| SCHEMBL19484938 | 0.65 | MEN1 (0.43) | MEN1KMT2AEPHX1POLB | |
| SCHEMBL583850 | 0.65 | — | — | |
| SCHEMBL25922318 | 0.65 | — | — | |
| SCHEMBL2601892 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| US-20200172575-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| US-8980245-B2 | PEG-interferon λ1 conjugates and methods of treating viral infections | NANOGEN PHARMACEUTICAL BIOTECHNOLOGY (VN) | 2015-03-17 | — | — | US | disclosed |
| US-20130230490-A1 | PEG-Interferon Lambda 1 Conjugates | NANOGEN PHARMACEUTICAL BIOTECHNOLOGY (VN) | 2013-09-05 | — | — | US | disclosed |
| US-8454947-B1 | PEG-interferon lambda 1 conjugates | NANOGEN PHARMACEUTICAL BIOTECHNOLOGY (VN) | 2013-06-04 | — | — | US | disclosed |
| US-8372833-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-20120095231-A1 | UREA DERIVATIVE | YANO TOSHISADA (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8088777-B2 | Urea derivative | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8084395-B2 | 4-aza indole derivatives and their use as fungicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-7919523-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919523-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20090203712-A1 | Urea Derivative | SHIONOGI &CO., LTD. | 2009-08-13 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042973-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MEN1 4418/4885KMT2A 864/4885EPHX1 2453/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | MEN1 1545/4885KMT2A 1224/4885EPHX1 1281/4885 |
| US-20130230490-A1 | PEG-Interferon Lambda 1 Conjugates | IFNG, IFNAR1, IGLV6-57 | MEN1 3401/4885KMT2A 4197/4885EPHX1 3175/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | MEN1 1824/4885KMT2A 3875/4885EPHX1 4322/4885 |
| US-20120095231-A1 | UREA DERIVATIVE | NPY5R, NPY1R, NPY2R | MEN1 2951/4885KMT2A 3557/4885EPHX1 4596/4885 |
| US-20200172575-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | KISS1R, VIP, NPY1R | MEN1 268/4885KMT2A 3979/4885EPHX1 3986/4885 |
| US-20090203712-A1 | Urea Derivative | NPY5R, NPY1R, NPY2R | MEN1 2927/4885KMT2A 3489/4885EPHX1 4592/4885 |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | IDO1, INMT, AZI2 | MEN1 1241/4885KMT2A 957/4885EPHX1 1979/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | MEN1 1545/4885KMT2A 1224/4885EPHX1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.